Peritoneal Dialysis – Meta-Analysis

Fang Y.a,b· Chen X.a,b· Zhong K.a,b· Ni Q.a,b· He Z.a,b· Qiao Y.a,b· Zhao Y.a,b· Li J.a,b· Yang H.a,b· Yang B.a,b

Author affiliations

aDepartment of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
bDepartment of Nephrology, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: January 14, 2022
Accepted: November 03, 2022
Published online: January 04, 2023

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 1

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Encapsulating peritoneal sclerosis (EPS) is an uncommon and harmful complication which may cause destructive outcomes. Matrix metalloproteinase-2 (MMP-2) as a protease can reduce constituents of the extracellular matrix and play a crucial role in the progression of EPS. As a new biomarker, MMP-2 may improve the detection rate of EPS patients in clinical work. In this review, we summarize the recent study of MMP-2 in different etiologies and the assessment of its application value and draw attention to its future directions.

© 2023 S. Karger AG, Basel

References Petrie MC, Traynor JP, Mactier RA. Incidence and outcome of encapsulating peritoneal sclerosis. Clin Kidney J. 2016 Aug;9(4):624–9. Brown MC, Simpson K, Kerssens JJ, Mactier RA; Scottish Renal Registry. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol. 2009 Jul;4(7):1222–9. Nakamoto H. Encapsulating peritoneal sclerosis: a clinician’s approach to diagnosis and medical treatment. Perit Dial Int. 2005 Apr;25(4_Suppl):S30–8. Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract. 2009;111(2):c149–c154. Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, Miyazaki M, Nakamoto H. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Nephron Clin Practperit Dial Int. 2005 Apr;25(Suppl 4):S83–95. discussion c154. Hirahara I, Inoue M, Okuda K, Ando Y, Muto S, Kusano E. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis: a multicentre study in Japan. Nephrol Dial Transpl. 2007;22(2):560–7. Chou CY, Tseng CC, Chen JB, Hung CC, Huang CC. A matrix metalloproteinase-2-based nomogram to assess the risk of encapsulating peritoneal sclerosis in peritoneal dialysis patients. Biomed Res Int. 2021 Jan 18;2021:6666441. Lopes Barreto D, Struijk DG, Krediet RT. Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis. Am J Kidney Dis. 2015 May;65(5):748–53. Ulger S, Kilic D, Demircioglu F, Demirtas CY, Pasaoglu OT. Circulating gelatinases are not prognostic of treatment response and survival in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy. J Cancer Res Ther. 2018;14(8):S90–6. Kandasamy AD, Chow AK, Ali MA, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res. 2010 Feb 1;85(3):413–23. Ertilav M, Timur O, Hür E, Bozkurt D, Nar H, Kologlu T, et al. What does the dialysate level of matrix metalloproteinase 2 tell us? Adv Perit Dial. 2011;27:6–10. Hirahara I, Ogawa Y, Kusano E, Asano Y. Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats. Nephrol Dial Transpl. 2004 Jul;19(7):1732–41. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003 May 2;92(8):827–39. Kim JJ, Li JJ, Kim KS, Kwak SJ, Jung DS, Ryu DR, et al. High glucose decreases collagenase expression and increases TIMP expression in cultured human peritoneal mesothelial cells. Nephrol Dial Transpl. 2008;23(2):534–41. Korte MR, Sampimon DE, Betjes MGH, Krediet RT. Encapsulating peritoneal sclerosis: the state of affairs. Nat Rev Nephrol. 2011 Aug 2;7(9):528–38. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. Perit Dial Int. 2000;20(4_Suppl):S43–55. Cho Y, Johnson DW, Vesey DA, Hawley CM, Pascoe EM, Clarke M, et al. Higher dialysate matrix metalloproteinase-2 levels are associated with peritoneal membrane dysfunction. Perit Dial Int. 2016 Jan-Feb;36(1):16–25. Barreto DL, Coester AM, Struijk DG, Krediet RT. Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients? Perit Dial Int. 2013 Sep-Oct;33(5):529–37. Lambie MR, Chess J, Summers AM, Williams PF, Topley N, Davies SJ, et al. Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study. Nephrol Dial Transpl. 2016 Mar;31(3):480–6. Nakao M, Yokoyama K, Yamamoto I, Matsuo N, Tanno Y, Ohkido I, et al. Risk factors for encapsulating peritoneal sclerosis in long-term peritoneal dialysis: a retrospective observational study. Ther Apher Dial. 2014 Feb;18(1):68–73. Mihalache O, Bugă C, Doran H, Catrina E, Bobircă F, Pătrașcu T. Encapsulating Peritoneal Sclerosis: a rare and serious complication of peritoneal dialysis: case series. J Med Life. 2014;7 Spec No. 3:8–12. Li D, Li Y, Zeng H, Wu Y. Risk factors for Encapsulating Peritoneal Sclerosis in patients undergoing peritoneal dialysis: a meta-analysis. PLoS One. 2022 Mar 21;17(3):e0265584. Jörres A. Innovative approaches to the preservation of the peritoneal membrane: from bench to bedside. Adv Ren Replace Ther. 2001 Jul;8(3):164–72. Ayuzawa N, Ishibashi Y, Takazawa Y, Kume H, Fujita T. Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan. Perit Dial Int. 2012 Mar-Apr;32(2):159–67. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int. 2005;25(3):248–55. Habib AM, Preston E, Davenport A. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial Transpl. 2010 May;25(5):1633–8. Nishina M, Endoh M, Suzuki D, Tanabe R, Endoh H, Hirahara I, et al. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Clin Exp Nephrol. 2004 Dec;8(4):339–43. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004 Oct;44(4):729–37. Masunaga Y, Hirahara I, Shimano Y, Kurosu M, Iimura O, Miyata Y, et al. A case of encapsulating peritoneal sclerosis at the clinical early stage with high concentration of matrix metalloproteinase-2 in peritoneal effluent. Clin Exp Nephrol. 2005 Mar;9(1):85–9. Hirahara I, Kusano E, Morishita Y, Inoue M, Akimoto T, Saito O, et al. Matrix metalloproteinase-2 as a superior biomarker for peritoneal deterioration in peritoneal dialysis. World J Nephrol. 2016 Mar 6;5(2):204–12. Kasai K, Terawaki H, Otsuka Y, Hamaguchi A, Kondo M, Tanno Y, et al. [Clinical evaluation of cases with massive ascites accumulation after discontinuation of CAPD: an attempt to establish the concept of the pre-sclerosing encapsulating peritonitis(pre-SEP) state]. Nihon Jinzo Gakkai Shi. 2000 May;42(4):346–52. Minetto Brabo A, Soares Do Carmo Reis N, Barretti P, Ponce D. A combination of corticosteroid, sirolimus, and intradialytic parenteral nutrition in encapsulating peritoneal sclerosis: case report and literature review. Hemodial Int. 2017 Jul;21(3):307–11. Maruyama Y, Nakayama M. Encapsulating peritoneal sclerosis in Japan. Perit Dial Int. 2008 Jun;28(3_Suppl):S201–4. Kuriyama S, Tomonari H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transpl. 2001 Jun;16(6):1304–5. Lafrance JP, Létourneau I, Ouimet D, Bonnardeaux A, Leblanc M, Mathieu N, et al. Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis. 2008 Feb;51(2):e7–10. Huddam B, Başaran M, Koçak G, Azak A, Yalçın F, Reyhan NH, et al. The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis. Int Urol Nephrol. 2015 Aug;47(8):1423–8. Hur E, Bozkurt D, Timur O, Bicak S, Sarsik B, Akcicek F, et al. The effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats. Clin Nephrol. 2012 Jan;77(01):1–7. Cornelis T, Oreopoulos DG. Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data. Int Urol Nephrol. 2011 Mar;43(1):147–56. Guest S. Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int. 2009 May-Jun;29(3):252–5. del Peso G, Bajo MA, Gil F, Aguilera A, Ros S, Costero O, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial. 2003;19:32–5. Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, Betjes MGH, et al. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transpl. 2011 Feb;26(2):691–7. Saglam F, Cavdar Z, Sarioglu S, Kolatan E, Oktay G, Yilmaz O, et al. Pioglitazone reduces peritoneal fibrosis via inhibition of TGF-β, MMP-2, and MMP-9 in a model of encapsulating peritoneal sclerosis. Ren Fail. 2012;34(1):95–102. Yamamoto D, Takai S, Hirahara I, Kusano E. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clinica Chim Acta. 2010 May 2;411(9–10):762–4. Yamamoto D, Takai S, Akimoto T, Hirahara I, Ito C, Muto S, et al. Matrix metalloproteinase-2 inhibition by temocapril and its important role in peritoneal transport. Clin Exp Pharmacol Physiol. 2012 Oct;39(10):864–8. Moinuddin Z, Summers A, Van Dellen D, Augustine T, Herrick SE. Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease. Front Physiol. 2014;5:470. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transpl. 2007 Oct;22(10):2838–48. Article / Publication Details

First-Page Preview

Received: January 14, 2022
Accepted: November 03, 2022
Published online: January 04, 2023

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 1

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.